TY - JOUR
T1 - The landscape of alterations in DNA damage response pathways in colorectal cancer
AU - Arai, Hiroyuki
AU - Elliott, Andrew
AU - Xiu, Joanne
AU - Wang, Jingyuan
AU - Battaglin, Francesca
AU - Kawanishi, Natsuko
AU - Soni, Shivani
AU - Zhang, Wu
AU - Millstein, Joshua
AU - Sohal, Davendra
AU - Goldberg, Richard M.
AU - Hall, Michael J.
AU - Scott, Aaron J.
AU - Khushman, Moh'd
AU - Hwang, Jimmy J.
AU - Lou, Emil
AU - Weinberg, Benjamin A.
AU - Marshall, John L.
AU - Lockhart, Albert C.
AU - Stafford, Phillip
AU - Zhang, Jian
AU - Moretto, Roberto
AU - Cremolini, Chiara
AU - Korn, W. Michael
AU - Lenz, Heinz Josef
N1 - Publisher Copyright:
© 2021 American Association for Cancer Research.
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Purpose: Defective DNA damage response (DDR) is a hallmark of cancer leading to genomic instability and is associated with chemosensitivity. Although the mismatch repair system has been extensively studied, the clinical implications of other mechanisms associated with DDR alterations in patients with colorectal cancer remain unclear. This study aimed to understand DDR pathways alterations and their association with common clinical features in patients with colorectal cancer. Experimental Design: Next-generation sequencing and whole-transcriptome sequencing were conducted using formalin-fixed paraffin-embedded samples submitted to a commercial Clinical Laboratory Improvement Amendments-certified laboratory. Samples with pathogenic or presumed pathogenic mutations in 29 specific DDR-related genes were considered as DDR-mutant (DDR-MT) and the remaining samples as DDR-wild type (DDR-WT). Results: Of 9,321 patients with colorectal cancer, 1,290 (13.8%) were DDR-MT. The frequency of DDR-MT was significantly higher in microsatellite instability-high (MSI-H) cases than in microsatellite stable cases (76.4% vs. 9.5%). The DDR-MT genotype was higher in the right-sided, RAS-wild, BRAF-mutant, and CMS1 subgroups. However, these associations were primarily confounded by the distribution of MSI status. Compared with the DDR-WT tumors, the DDR-MT tumors had a higher mutational burden and gene expression levels in the immune-related pathway, which were independent of MSI status. Conclusions: We characterized a distinct subgroup of patients with colorectal cancer with tumors harboring mutations in the DDR-related genes. These patients more commonly had MSI-H tumors and exhibited an activated immune signature regardless of their tumor's MSI status. These findings warrant further investigations to develop personalized treatment strategies in this significant subgroup of patients with colorectal cancer.
AB - Purpose: Defective DNA damage response (DDR) is a hallmark of cancer leading to genomic instability and is associated with chemosensitivity. Although the mismatch repair system has been extensively studied, the clinical implications of other mechanisms associated with DDR alterations in patients with colorectal cancer remain unclear. This study aimed to understand DDR pathways alterations and their association with common clinical features in patients with colorectal cancer. Experimental Design: Next-generation sequencing and whole-transcriptome sequencing were conducted using formalin-fixed paraffin-embedded samples submitted to a commercial Clinical Laboratory Improvement Amendments-certified laboratory. Samples with pathogenic or presumed pathogenic mutations in 29 specific DDR-related genes were considered as DDR-mutant (DDR-MT) and the remaining samples as DDR-wild type (DDR-WT). Results: Of 9,321 patients with colorectal cancer, 1,290 (13.8%) were DDR-MT. The frequency of DDR-MT was significantly higher in microsatellite instability-high (MSI-H) cases than in microsatellite stable cases (76.4% vs. 9.5%). The DDR-MT genotype was higher in the right-sided, RAS-wild, BRAF-mutant, and CMS1 subgroups. However, these associations were primarily confounded by the distribution of MSI status. Compared with the DDR-WT tumors, the DDR-MT tumors had a higher mutational burden and gene expression levels in the immune-related pathway, which were independent of MSI status. Conclusions: We characterized a distinct subgroup of patients with colorectal cancer with tumors harboring mutations in the DDR-related genes. These patients more commonly had MSI-H tumors and exhibited an activated immune signature regardless of their tumor's MSI status. These findings warrant further investigations to develop personalized treatment strategies in this significant subgroup of patients with colorectal cancer.
KW - Colorectal Neoplasms/genetics
KW - DNA Damage/genetics
KW - Drug Resistance, Neoplasm/genetics
KW - Female
KW - Genomic Instability/genetics
KW - Humans
KW - Male
KW - Microsatellite Instability
KW - Mutation
UR - http://www.scopus.com/inward/record.url?scp=85106968367&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000657419800028&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1158/1078-0432.CCR-20-3635
DO - 10.1158/1078-0432.CCR-20-3635
M3 - Article
C2 - 33766816
SN - 1078-0432
VL - 27
SP - 3234
EP - 3242
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 11
ER -